aTyr Pharma ATYR Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$70.03M+5.5% | -$74.12M+1.3% | -$75.13M-12.7% | -$66.64M-5.1% | -$63.42M+0.9% | ||
| $659K-0.8% | $664K-1.3% | $673K-1.9% | $686K-1.6% | $697K-1.6% | ||
| $5.13M+2.6% | $5M+9.6% | $4.56M+13.9% | $4.01M+16.9% | $3.43M+14.7% | ||
| $822K+2,591% | -$33K— | —— | —— | —— | ||
| -$5.98M+25.7% | -$8.05M— | —— | —— | —— | ||
| $905K+1.8% | $889K— | —— | —— | —— | ||
| -$740K-4.1% | -$711K— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$59.08M+4.7% | -$61.99M+1.5% | -$62.92M-13.2% | -$55.6M+10.5% | -$62.16M+10.1% | ||
| $215K+179% | $77K+8.5% | $71K+44.9% | $49K+2.1% | $48K-26.2% | ||
| $76.21M-18.4% | $93.45M-12.4% | $106.67M+51.9% | $70.24M-0.9% | $70.87M+2.6% | ||
| $87.27M-1.3% | $88.46M+11.8% | $79.15M-2.3% | $81.02M-4.8% | $85.08M-1.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $19K+850% | $2K— | ||
| $550K+2.0% | $539K+2.1% | $528K+2.1% | $517K+2.0% | $507K+2.0% | ||
| $47.37M-28.4% | $66.14M-22.2% | $84.98M+53.5% | $55.36M+8.8% | $50.87M+27.3% | ||
| —— | —— | -$5.52M— | —— | —— | ||
| $83K-11.7% | $94K-10.5% | $105K-9.5% | $116K-8.7% | $127K-7.3% | ||
| $1.59M-14.5% | $1.85M-9.3% | $2.04M-4.5% | $2.14M-11.5% | $2.42M-10.6% | ||
| $5.13M+2.6% | $5M+9.6% | $4.56M+13.9% | $4.01M+16.9% | $3.43M+14.7% | ||
| -$740K-4.1% | -$711K— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$5.98M+25.7% | -$8.05M— | —— | —— | —— | ||
| $905K+1.8% | $889K— | —— | —— | —— | ||
| $87.27M-1.3% | $88.46M+11.8% | $79.15M-2.3% | $81.02M-4.8% | $85.08M-1.5% | ||
| $550K+2.0% | $539K+2.1% | $528K+2.1% | $517K+2.0% | $507K+2.0% | ||
| $47.69M-28.2% | $66.44M-22.2% | $85.35M+53.5% | $55.62M+8.7% | $51.17M+27.1% | ||
| —— | —— | —— | $19K+850% | $2K— | ||
| -$740K-4.1% | -$711K— | —— | —— | —— | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | —— | —— | —— | —— | ||
| -$59.3M+4.5% | -$62.06M+1.5% | -$62.99M-13.2% | -$55.65M+10.5% | -$62.21M+10.1% | ||
| -$59.3M+4.5% | -$62.06M+1.5% | -$62.99M-13.2% | -$55.65M+10.5% | -$62.21M+10.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does aTyr Pharma generate?
- aTyr Pharma (ATYR) generated -$59.1M in operating cash flow over the trailing twelve months.
- What is aTyr Pharma's free cash flow?
- After $215.0K of capital expenditures, aTyr Pharma's free cash flow was -$59.3M over the trailing twelve months, up 4.7% year over year.
- Where does aTyr Pharma's cash flow data come from?
- Every line is extracted from aTyr Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
